Get started
Author

Dean M. Najarian

Observed names: D. Najarian, Dean Najarian
ORCID: 0000-0002-2556-2144
Observed ORCID: 0000-0002-2556-2144
OpenAlex ID: A5064130565
Olanzapine Increases Weight and Serum Triglyceride Levels
1999 · David N. Osser, Dean M. Najarian, et al. · The Journal of Clinical Psychiatry · 227
A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia
2021 · Dean Najarian, Panna Sanga, et al. · The International Journal of Neuropsychopharmacology · 68
Community pharmacists and mental illness: a survey of service provision, stigma, attitudes and beliefs
2018 · Vincent Giannetti, Charles F. Caley, et al. · International Journal of Clinical Pharmacy · 63
The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia
2023 · Ruth Milz, Carmela Benson, et al. · Neuropsychiatric Disease and Treatment · 49
PDF
Practical considerations for managing breakthrough psychosis and symptomatic worsening in patients with schizophrenia on long-acting injectable antipsychotics
2018 · Christoph U. Correll, Jennifer Kern Sliwa, et al. · CNS Spectrums · 27
PDF
Long-Term Efficacy and Safety of Paliperidone 6-Month Formulation: An Open-Label 2-Year Extension of a 1-Year Double-Blind Study in Adult Participants With Schizophrenia
2023 · Dean Najarian, Ibrahim Turkoz, et al. · The International Journal of Neuropsychopharmacology · 23
PDF
An assessment of injection site reaction and injection site pain of 1-month and 3-month long-acting injectable formulations of paliperidone palmitate
2018 · Jennifer Kern Sliwa, Adam Savitz, et al. · Perspectives In Psychiatric Care · 14
PDF
Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate
2018 · Maju Mathews, Isaac Nuamah, et al. · Neuropsychiatric Disease and Treatment · 9
PDF
Comparing Relapse Rates in Real-World Patients with Schizophrenia Who Were Adequately versus Not Adequately Treated with Paliperidone Palmitate Once-Monthly Injections Before Transitioning to Once-Every-3-Months Injections
2022 · Ibrahim Turkoz, Mehmet Daskiran, et al. · Neuropsychiatric Disease and Treatment · 4
PDF
PM410. Comparison of 3-Monthly versus 1-Monthly Paliperidone Palmitate for Time to Onset and Time to Resolution of Extrapyramidal Symptoms in Patients with Exacerbated Schizophrenia
2016 · Maju Mathews, Isaac Nuamah, et al. · The International Journal of Neuropsychopharmacology · 3
Earlier Use of Long-Acting Injectable Paliperidone Palmitate Versus Oral Antipsychotics in Patients With Schizophrenia
2023 · Oliver J. Lopena, Larry D. Alphs, et al. · The Journal of Clinical Psychiatry · 2
PDF
Long-term efficacy and safety of paliperidone 6-month formulation: An open-label extension of a double-blind study in adult patients with schizophrenia
2023 · D. Najarian, I. Turkoz, et al. · European Psychiatry · 2
PDF
Baseline risk characterization of early versus later adopters of long‐acting paliperidone palmitate formulations
2022 · Daniel Fife, Stephen Fortin, et al. · Neuropsychopharmacology Reports · 1
PM386. An Assessment of Injection Site Reactions and Injection Site Pain of Once-Every One Month and Three-Month Long-Acting Injectable Formulations of Paliperidone Palmitate
2016 · Erica Elefant, Jennifer Kern Sliwa, et al. · The International Journal of Neuropsychopharmacology · 1
PDF
Importance of Long-Acting Injectable Antipsychotic Preparation, Administration, and Injection Site Tolerability: A Focus on Paliperidone Palmitate Once-Every-6-Months Formulation
2023 · Steven Krozer, Karen L. Johnston, et al. · Perspectives In Psychiatric Care
PDF
P.0533 Paliperidone palmitate 6-month long-acting injectable for schizophrenia: A randomised, double-blind, multicenter, noninferiority phase 3 study
2021 · D. Najarian, P. Sanga, et al. · European Neuropsychopharmacology
F110. Symptomatic Remission With Paliperidone Palmitate 3-monthly Formulation in Schizophrenia Patients in a Clinical Practice Setting
2019 · M P Garcia-Portilla, P M Llorca, et al. · Schizophrenia Bulletin
PDF
Works count: 17
Citation count: 493
H-index: 8
I10-index: 7
Year
Topic
Type